Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Why Aditxt Stock Is Volatile Today

By Erica Kollmann
April 2, 12:42 PM
Aditxt's wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction. Appili has developed FDA-approved Likmez (previously ATI-1501), its ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the U.S Department of Defense, and its ATI-1801 topical formulation targeting cutaneous leishmaniasis.

ADTX

Read More
1 minute read

Aditxt, Through Adivir Subsidiary, To Acquire All Issued And Outstanding Class A Common Shares Of Appili; Appili Shareholders To Receive 0.002745004 Shares Of Aditxt And $0.0467 For Each Appili Share Held, Representing Total Consideration Of ~$0.0561

By Benzinga Newsdesk
April 2, 7:35 AM
Under the terms of the Arrangement Agreement, shareholders of Appili (the "Appili Shareholders") will receive (i) 0.002745004 of a share of common stock (each whole share, an "Aditxt Share") of Aditxt (the "Share

ADTX

Read More
2 minute read

Reported December 29, 2023, Aditxt Announced A $6M Private Placement Of 1,237,114 Shares Of Common Stock At A Price Of $4.85/Share And Accompanying Warrant, Priced At-The-Market Under Nasdaq Rules

By Benzinga Newsdesk
January 2, 12:15 PM
Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered

ADTX